Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice

British Journal of Cancer

Volumn 101, Issue 10, 2009, Pages 1683-1691

  Ganai, S ^a,b   Arenas, R B ^a,b,c   Forbes, N S ^a,c,d  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Pioneer Valley Life Sciences Institute   (United States)

^d University of Massachusetts   (United States)

Author keywords

Attenuated Salmonella typhimurium; RecA; Spatiotemporal controlled delivery; Targeted cancer therapy; TRAIL

Indexed keywords

CASPASE 3; RECA PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER SURVIVAL; CANCER THERAPY; CARCINOMA CELL; CONTROLLED STUDY; DEATH; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUOROMETRY; GAMMA IRRADIATION; IMMUNOBLOTTING; IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION; RISK REDUCTION; SALMONELLA TYPHIMURIUM; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PROMOTER REGIONS, GENETIC; REC A RECOMBINASES; SALMONELLA TYPHIMURIUM; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 70449533849     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605403     Document Type: Article

References (50)

1. Anderson DG, Kowalczykowski SC (1998) Reconstitution of an SOS response pathway: derepression of transcription in response to DNA breaks. Cell 95: 975-979
2. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162
3. Barbe S, Van Mellaert L, Theys J, Geukens N, Lammertyn E, Lambin P, Anne J (2005) Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol Lett 246: 67-73
4. Beg AA, Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782-784
5. Belka C, Jendrossek V, Pruschy M, Vink S, Verheij M, Budach W (2004) Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol, Biol, Phys 58: 542-554
6. Corsten MF, Hofstra L, Narula J, Reutelingsperger CP (2006) Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance. Cancer Res 66: 1255-1260
7. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ (2006) TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 84: 87-98
8. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B (2001) Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 98: 15155-15160
9. Dresselaers T, Theys J, Nuyts S, Wouters B, de Bruijn E, Anne J, Lambin P, Van Hecke P, Landuyt W (2003) Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours. Br J Cancer 89: 1796-1801
10. Dubois L, Dresselaers T, Landuyt W, Paesmans K, Mengesha A, Wouters BG, Van Hecke P, Theys J, Lambin P (2007) Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression. Br J Cancer 96: 758-761
11. Forbes NS (2006) Profile of a bacterial tumor killer. Nat Biotechnol 24: 1484-1485
12. Forbes NS, Munn LL, Fukumura D, Jain RK (2003) Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res 63: 5188-5193
13. Groot AJ, Mengesha A, van der Wall E, van Diest PJ, Theys J, Vooijs M (2007) Functional antibodies produced by oncolytic clostridia. Biochem Biophys Res Commun 364: 985-989
14. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA (2005) The anti-tumor effect of Apo2 L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3: 22
15. Jain RK, Forbes NS (2001) Can engineered bacteria help control cancer? Proc Natl Acad Sci USA 98: 14748-14750
16. Kasinskas RW, Forbes NS (2006) Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng 94: 710-721
17. Kasinskas RW, Forbes NS (2007) Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res 67: 3201-3209
18. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA (2001) Preclinical studies to predict the disposition of Apo2 L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299: 31-38
19. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y, El-Deiry WS (2004) Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 279: 40044-40052
20. LeBlanc HN, Ashkenazi A (2003) Apo2 L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75
21. Lee CH, Wu CL, Shiau AL (2004) Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 6: 1382-1393
22. Lee CH, Wu CL, Shiau AL (2005) Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther 12: 175-184
23. Lemmon MJ, van Zijl P, Fox ME, Mauchline ML, Giaccia AJ, Minton NP, Brown JM (1997) Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Therapy 4: 791-796
24. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Luo X, Miller SI, Zheng L, King I, Pawelek JM, Bermudes D (1999) Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 17: 37-41
25. McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK (2001) Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature 413: 852-856
26. McLoughlin JM, McCarty TM, Cunningham C, Clark V, Senzer N, Nemunaitis J, Kuhn JA (2005) TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol 12: 825-830
27. Mezhir JJ, Smith KD, Posner MC, Senzer N, Yamini B, Kufe DW, Weichselbaum RR (2006) Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther 13: 1-6
28. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592
29. Mitchell RJ, Gu MB (2004) An Escherichia coli biosensor capable of detecting both genotoxic and oxidative damage. Appl Microbiol Biotechnol 64: 46-52
30. Mothersill CE, Moriarty MJ, Seymour CB (2004) Radiotherapy and the potential exploitation of bystander effects. Int J Radiat Oncol, Biol, Phys 58: 575-579
31. Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, Cahill A, Clairmont C, Sznol M (2003) Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cyto-sine deaminase gene in refractory cancer patients. Cancer Gene Ther 10: 737-744
32. Nuyts S, Van Mellaert L, Barbe S, Lammertyn E, Theys J, Landuyt W, Bosmans E, Lambin P, Anne J (2001a) Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters. Appl Environ Microbiol 67: 4464-4470
33. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Bosmans E, Anne J, Lambin P (2001b) Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2Gy irradiation. Gene Therapy 8: 1197-1201
34. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N (2004) TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 22: 592-601
35. Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ (2008) Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 100: 649-662
36. Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA (2007) Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 297: 151-162
37. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ (2007) Targeting death-inducing receptors in cancer therapy. Oncogene 26: 3745-3757
38. Theys J, Landuyt W, Nuyts S, Van Mellaert L, van Oosterom A, Lambin P, Anne J (2001) Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 8: 294-297
39. Theys J, Pennington O, Dubois L, Anlezark G, Vaughan T, Mengesha A, Landuyt W, Anne J, Burke PJ, Durre P, Wouters BG, Minton NP, Lambin P (2006) Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 95: 1212-1219
40. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA (2002) Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20: 142-152
41. Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441-1454
42. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163 (Pubitemid 29068521)
43. Wei MQ, Mengesha A, Good D, Anne J (2008) Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 259: 16-27
44. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K (2004) TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-783
45. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y, Taniguchi S (2001) Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 66: 165-170 (Pubitemid 32521423)
46. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science 295: 1526-1528
47. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, Goebel W, Szalay AA (2004) Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 22: 313-320
48. Zhao M, Geller J, Ma H, Yang M, Penman S, Hoffman RM (2007) Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 104: 10170-10174
49. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, Penman S, Hoffman RM (2005) Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 102: 755-760 (Pubitemid 40282738)
50. Zheng SJ, Wang P, Tsabary G, Chen YH (2004) Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 113: 58-64